A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

计划入组 248 人 · 首次发布于 2023 年 10 月 5 日

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

计划入组 199 人 · 首次发布于 2010 年 8 月 3 日

A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

计划入组 123 人 · 首次发布于 2008 年 4 月 15 日

Antisense oligonucleotides

Parkinson's disease therapeutics

Parkinson's disease(CuroNZ)

ACADIA Pharmaceuticals

United States

THE PARKINSON'S AND MOVEMENT DISORDER INSTITUTE

United States

Rare Disease Research, LLC

NH130 Shows Promise in Phase I Trial for Parkinson's Disease Psychosis

Acadia Pharmaceuticals Wins Patent Infringement Case Against Aurobindo for Parkinson's Drug Nuplazid

Acadia Pharmaceuticals Secures Patent Victory for Parkinson's Drug Nuplazid Until 2038